Is Better Standardization of Therapeutic Antibody Quality in Emerging Diseases Epidemics Possible?

ABSTRACT: During the ongoing COVID-19 epidemic many efforts have gone into the investigation of the SARS-CoV-2-specific antibodies as possible therapeutics. Currently, conclusions cannot be drawn due to the lack of standardization in antibody assessments. Here we describe an approach of establishing antibody characterisation in emergent times which would, if followed, enable comparison of results from different studies. The key component is a reliable and reproducible assay of wild-type SARS-CoV-2 neutralisation based on a banking system of its biological components - a challenge virus, cells and an anti-SARS-CoV-2 antibody in-house standard, calibrated to the First WHO International Standard immediately upon its availability. Consequently, all collected serological data were retrospectively express

SUBMITTER: Ravlic S 

PROVIDER: S-EPMC8902244 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature